Search results
Showing 631 to 645 of 2208 results for guidelines
COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services (NG179)
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Read biographies for all members of NICE's indicator advisory committee.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA170Show all sections
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.